Trial Profile
A Phase II Clinical Study Using OCZ103-OS in Patients With Unresectable and Locally Recurrent or Metastatic Colorectal Cancer Undergoing Standard Chemotherapy (mFOLFOX6 or FOLFIRI) as Second-Line Treatment
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Pentamidine (Primary) ; Fluorouracil; Folinic acid; Irinotecan; Oxaliplatin
- Indications Colorectal cancer
- Focus Therapeutic Use
- Sponsors Oncozyme Pharma
- 20 Oct 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 20 Feb 2013 Planned End Date changed from 1 Feb 2014 to 1 Jul 2014 as reported by ClinicalTrials.gov.
- 20 Feb 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.